Veradermics' (MANE) VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss, the company said Wednesday.

The orally-administered extended-release formulation showed improvement in hair coverage as early as the second month and "consistent treatment effect" with around 88.9% dosed once a day and 90.0% with those dosed twice a day reporting "improved" or "much improved" results after six months, the company said.

VDPHL01 also showed a "favorable" safety and tolerability profile consistent with previous trials, the company said.

Veradermics is planning a phase 2/3 clinical trial with results expected in H1 2027, the company said.

Shares of the company were up 4.8% in recent premarket trading.